DIAGNOS Announces a 3-Year Contract with Cielo Vista Eye Clinic in Mexico
September 14 2021 - 9:00AM
Diagnos Inc. (“
DIAGNOS” or “the
Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA:
4D4A), a leader in early detection of certain critical health
issues, announces the signing of a 3-year contract with Cielo Vista
Eye Clinic (“Cielo”). DIAGNOS will supply its CARA platform and
enable Cielo to screen its patients for Diabetic Macular Edema and
Diabetic Retinopathy.
Cielo is an ophthalmologic clinic located in the
City of Jerez, State of Zacatecas, Mexico. Founded in 1996, they
specialize in comprehensive ophthalmic assessments, optometric
services, treatment of eye diseases and microsurgeries, treating
and serving over 16,000 patients per year. Cielo currently uses the
Spanish version of our CARA platform to screen their at-risk
clients such as diabetic patients.
“The Cielo Vista Eye Clinic is pleased to team
up with DIAGNOS to assist in the automatic early detection of
Diabetes-related health issues. We have validated DIAGNOS’
technology through a pilot project and are now pleased to use this
technology full-time. This will assist us to care for a
significantly increasing number of patients with avoidable
blindness due to Diabetes.” Dre. María López
Vitolas and Dr. Jesús Rodríguez Pinedo,
ophthalmologists and founders of Cielo Vista Eye Clinic.
“Cielo Vista Eye Clinic specializes in the diagnosis, treatment and
monitoring of any type of visual problem, we use the most modern
surgical techniques and technology to detect and correct vision
problems including Diabetic Retinopathy”, concluded Dre.
López and Dr. Rodríguez.
“Our goal over the next 3 years to assist Cielo
in becoming the national reference for early detection of
Diabetes-related eye issues. We are excited to embark on this
journey in which we will actively support our partner in its daily
operations to detect and treat Diabetic Retinopathy and Macular
Edema. At DIAGNOS it is our commitment to co-work with specialists
and provide our AI platform to assist in identifying rapidly and
accurately diverse pathologies that need to be treated or
monitored. Diabetic Retinopathy is a symptomless disease that can
lead to blindness if not treated in its early stages.” said
Mr. Andre Larente, President of DIAGNOS.
About Cielo Vista Eye
ClinicCielo has been dedicated to providing
ophthalmological services. It specializes in the diagnosis,
treatment and monitoring of any type of visual problem using state
of the art techniques and technologies. For more than 20 years,
Cielo has been treating and serving over 16 000 patients and
customers with eye related issues per year. We strive to contribute
to the well-being of the members of our community.
Additional information is available at
https://cielovistaojos.com/
About DIAGNOSDIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com.
This press release contains forward-looking
information. We cannot guarantee that the forward-looking
information mentioned will prove to be accurate, as there may be a
significant discrepancy between actual results or future events and
those mentioned in this statement. DIAGNOS disclaims any intention
or obligation to publicly update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise. The forward-looking information contained in this
press release is expressly covered by this caution.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Corporate Communications:
Nancy Massicotte
IR Pro Communications Inc.
Dir: +1 604-507-3377
TF: 1-866-503-3377
Email: nancy@irprocommunications.com
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024